Vilon

Vilon is the Lys-Glu (KE) dipeptide — the shortest synthetic peptide bioregulator in the Khavinson bioregulator series. It is one of three active fractions isolated from Thymalin (the heterogeneous calf thymus extract), alongside Crystagen (EDP) and Thymogen (EW). As the dipeptide fraction, Vilon represents the minimal pharmacophore of thymic peptide activity: two amino acids that retain measurable biological effects in cell and animal models.

Vilon has a published animal lifespan extension study (PMID 10944717) — one of the few Khavinson bioregulators with this type of longitudinal outcome data. In CBA female mice, Vilon inhibited spontaneous tumor growth and extended mean lifespan compared to untreated controls.

Vilon acts through the Khavinson-class epigenetic mechanism: progressive activation of facultative heterochromatin in aging cells. The KE dipeptide is proposed to: - Bind regulatory DNA sequences, particularly in immune cell loci - Induce de-heterochromatinization in aged lymphocytes and other immune cells - Restore expression of immune surveillance and anti-tumor genes silenced by age-related chromatin condensation - Enhance NK cell activity and immune surveillance function

The anti-tumor effect observed in mice is proposed to result from restored immune surveillance capacity — specifically NK cell and cytotoxic T-cell activity against early spontaneous tumors that normally escape immunosenescent immune systems.

Vilon also shares immune-modulating properties with its parent compound Thymalin, including T-cell normalization and cytokine balance restoration, consistent with the thymic peptide class effect of counteracting immunosenescence.